Preclinical |
Analysis in non-human subjects, to preliminary evaluate efficacy, toxicity and pharmacokinetics |
– |
Phase 0 |
Preliminary evaluation of efficacy, effectiveness and safety in healthy volunteers |
10–20 |
Phase I |
Preliminary evaluation of efficacy, effectiveness and safety in healthy volunteers |
20–100 |
Phase II |
Evaluation of efficacy, effectiveness and safety in patients |
100–300 |
Phase III |
Evaluation of efficacy, effectiveness and safety in patients |
>300 |
Phase IV |
Postmarketing surveillance |
All subjects |